The company, which is already in phase 2 clinical trials with a treatment for celiac disease, has announced the FDA has accepted their Investigational New Drug (IND) application for evaluation of CNP-201, A treatment for peanut allergy. that reduces the need for strict peanut avoidance and reduces the potentially fatal health risks associated with peanut allergy.
By transplanting fecal microbes from healthy and food-allergic infants to germ-free mice (who do not possess a microbiome), investigators found that the healthy infant microbiota was protective against the development of food allergies.
Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.
We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.
Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.